<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04903184</url>
  </required_header>
  <id_info>
    <org_study_id>RUTICOVID19-ARG</org_study_id>
    <nct_id>NCT04903184</nct_id>
  </id_info>
  <brief_title>Exploratory Study to Evaluate the Efficacy of RUTI® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers</brief_title>
  <official_title>A Exploratory Phase II Clinical Trial, Double-blind, Randomized Placebo-controlled to Evaluate the Efficacy of RUTI® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RUTI Immunotherapeutics S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RUTI Immunotherapeutics S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to explore potential for reduction of incidence and/or morbidity of&#xD;
      SARS-CoV-2 infection in healthcare personnel. The study will include a comparison between&#xD;
      placebo and RUTI® vaccine in a 2:1 design.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Documented cumulative incidence of SARS-CoV-2 infection</measure>
    <time_frame>6 months</time_frame>
    <description>Percent of positive serology at the end of the study or positive PCR test in the course of routine clinical practice</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sick leave for SARS-CoV-2</measure>
    <time_frame>6 months</time_frame>
    <description>Number of days of documented sick leave for SARS-CoV-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days off work due to the quarantine</measure>
    <time_frame>6 months</time_frame>
    <description>The number of days off work due to the quarantine imposed as a consequence to have acute respiratory symptoms, fever or infection documented by SARS-CoV-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quarantine imposed by close contact outside the center with SARS-CoV-2 positive</measure>
    <time_frame>6 months</time_frame>
    <description>Number of days of quarantine imposed by close contact outside the center with SARS-CoV-2 positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever</measure>
    <time_frame>6 months</time_frame>
    <description>Number of days of self-reported fever (≥38 ºC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of self-reported acute respiratory symptoms</measure>
    <time_frame>6 months</time_frame>
    <description>Cumulative incidence of self-reported acute respiratory symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of self-reported acute respiratory symptoms</measure>
    <time_frame>6 months</time_frame>
    <description>Number of days of self-reported acute respiratory symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pneumonia</measure>
    <time_frame>6 months</time_frame>
    <description>Presence of compatible symptoms and radiological or tomographic focal alteration in the context of a confirmed diagnosis of Covid-19 infection and without evidence of other concomitant pathologies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of death from SARS-CoV-2 infection</measure>
    <time_frame>6 months</time_frame>
    <description>Cumulative incidence of death from documented SARS-CoV-2 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of admissions to Intensive Care Unit (ICU)</measure>
    <time_frame>6 months</time_frame>
    <description>Cumulative incidence of admissions to intensive care unit for documented SARS-CoV-2 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days in ICU</measure>
    <time_frame>6 months</time_frame>
    <description>Number of days admitted to the ICU for documented SARS-CoV-2 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of mechanical ventilation</measure>
    <time_frame>6 months</time_frame>
    <description>Cumulative incidence of need for mechanical ventilation due to documented SARS-CoV-2 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hospital admissions</measure>
    <time_frame>6 months</time_frame>
    <description>Cumulative incidence of hospital admissions for documented SARS-CoV-2 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of hospitalization</measure>
    <time_frame>6 months</time_frame>
    <description>Number of days of hospitalization for documented SARS-CoV-2 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of SARS-CoV-2 antibodies</measure>
    <time_frame>Study completion, an average of 1 year</time_frame>
    <description>Incidence of SARS-CoV-2 antibodies at the end of the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Types of antibodies detected</measure>
    <time_frame>Study completion, an average of 1 year</time_frame>
    <description>Frequency of immunoglobulin IgG and immunoglobulin IgM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of SARS-CoV-2 antibodies</measure>
    <time_frame>Study completion, an average of 1 year</time_frame>
    <description>Levels of SARS-CoV-2 antibodies</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>All adverse events reported by the subjects, both serious and non-serious, will be collected. All events related to a SARS-CoV-2 infection will be exempted from collection as part of the associated symptoms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">369</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Group RUTI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two dose of RUTI® vaccine at the baseline visit and after 2 weeks +/- 3 days, which will be administered subcutaneously in the deltoid region at a dose of 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli in an injection volume of 0.3 mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive two dose of physiological serum will be administered subcutaneously in the deltoid region at the baseline visit and after 2 weeks +/- 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RUTI® vaccine</intervention_name>
    <description>Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli in a total volum of 0,3mL.</description>
    <arm_group_label>Group RUTI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Physiological serum, 0.9% NaCl, will be used as a placebo.</description>
    <arm_group_label>Group Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sign the Informed Consent before initiating the selection procedures.&#xD;
&#xD;
          2. Population:&#xD;
&#xD;
               1. Healthcare system workers working in contact with subjects potentially infected&#xD;
                  with SARS-CoV-2&#xD;
&#xD;
               2. People between 18 years and 59 years&#xD;
&#xD;
          3. Willingness to meet the requirements of the protocol.&#xD;
&#xD;
          4. Negative Rapid Serological Test of SARS-CoV-2&#xD;
&#xD;
          5. The participant must agree to use effective contraceptive methods during the study&#xD;
             period, in case of childbearing age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous SARS-CoV-2 infection&#xD;
&#xD;
          2. Pregnancy. Pregnancy test will be performed in case of doubt.&#xD;
&#xD;
          3. Breastfeeding.&#xD;
&#xD;
          4. Suspected of active viral or bacterial infection.&#xD;
&#xD;
          5. Symptoms compatible with COVID-19, despite a negative polymerase chain reaction (PCR)&#xD;
             test.&#xD;
&#xD;
          6. Vaccination in the last 4 weeks or planned vaccination during the study period, except&#xD;
             for influenza vaccine.&#xD;
&#xD;
          7. Participation in a research that requires experimental intervention (does not include&#xD;
             observational studies) in the previous month before signing the Consent or during the&#xD;
             study.&#xD;
&#xD;
          8. Severely immunocompromised people. This exclusion category includes:&#xD;
&#xD;
               -  Subjects with human immunodeficiency virus (HIV-1).&#xD;
&#xD;
               -  Neutropenic subjects with less than 500 neutrophils / mm3.&#xD;
&#xD;
               -  Subjects with solid organ transplantation.&#xD;
&#xD;
               -  Subjects with bone marrow transplantation.&#xD;
&#xD;
               -  Subjects undergoing chemotherapy.&#xD;
&#xD;
               -  Subjects with primary immunodeficiency.&#xD;
&#xD;
               -  Severe lymphopenia with less than 400 lymphocytes / mm3.&#xD;
&#xD;
          9. Malignancy, or active solid or non-solid lymphoma from the previous two years.&#xD;
&#xD;
         10. Soy allergy.&#xD;
&#xD;
         11. Direct involvement in the design or execution of the RUTICOVID19 clinical trial.&#xD;
&#xD;
         12. Retirement, transfer, long-term leave (&gt; 1 month) due to scheduled surgery or any&#xD;
             other event that makes it impossible to work in person at your health center during&#xD;
             the months following the recruitment to the study.&#xD;
&#xD;
         13. Do not have a smartphone.&#xD;
&#xD;
         14. Detection by the researcher of lack of knowledge or willingness to participate and&#xD;
             comply with all requirements of the protocol.&#xD;
&#xD;
        16. Any other findings that, at the discretion of the researcher, may compromise compliance&#xD;
        with the protocol or that may influence significantly the interpretation or the results of&#xD;
        the effects of the vaccine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital General de Agudos Dr. Ignacio Pirovano</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Antoniewicz</last_name>
      <phone>+54 9 11 2481 5151</phone>
      <email>mariana.antoniewicz@latresearch.com</email>
    </contact>
    <investigator>
      <last_name>Ricardo Teijeiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Antoniewicz</last_name>
      <phone>+54 9 11 2481 5151</phone>
      <email>mariana.antoniewicz@latresearch.com</email>
    </contact>
    <investigator>
      <last_name>Baldo Belloso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Antoniewicz</last_name>
      <phone>+54 9 11 2481 5151</phone>
      <email>mariana.antoniewicz@latresearch.com</email>
    </contact>
    <investigator>
      <last_name>Victor Bittar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital José Néstor Lencinas</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Antoniewicz</last_name>
      <phone>+54 9 11 2481 5151</phone>
      <email>mariana.antoniewicz@latresearch.com</email>
    </contact>
    <investigator>
      <last_name>Maria Andrea Villalba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Materno Infantil &quot;Dr. Héctor Quintana&quot;</name>
      <address>
        <city>San Salvador De Jujuy</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Antoniewicz</last_name>
      <phone>+54 9 11 2481 5151</phone>
      <email>mariana.antoniewicz@latresearch.com</email>
    </contact>
    <investigator>
      <last_name>Martín Caruso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas Presidente Dr. Nicolás Avellaneda</name>
      <address>
        <city>Tucumán</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Antoniewicz</last_name>
      <phone>+54 9 11 2481 5151</phone>
      <email>mariana.antoniewicz@latresearch.com</email>
    </contact>
    <investigator>
      <last_name>Conrado Llapur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

